

Global iPSC-Derived Cell Therapy Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G5D9D4DC4ABEEN.html>

Date: August 2026

Pages: 133

Price: US\$ 4,480.00 (Single User License)

ID: G5D9D4DC4ABEEN

Abstracts

The global iPSC-Derived Cell Therapy market size is expected to reach \$ 22604 million by 2032, rising at a market growth of 11.2% CAGR during the forecast period (2026-2032).

iPSC-Derived Cell Therapy refers to living cell therapeutic products manufactured from induced pluripotent stem cells (iPSCs) through processes including directed differentiation, purification, expansion, genetic engineering, and quality release testing. These products encompass multiple cell types such as NK/T immune cells, neural progenitor cells, cardiomyocytes, pancreatic islet cells, retinal cells, and mesenchymal stromal cells. They are being developed for applications in oncology, Parkinson's disease, heart failure, diabetes, retinal degenerative diseases, and inflammatory tissue repair. The platform emphasizes lineage consistency, genomic stability, control of residual undifferentiated cells, immune matching strategies, cryopreserved formulation, and clinical-grade GMP scalable manufacturing capabilities. The overall gross margin is approximately 65%.

Demand for iPSC-derived cell therapies is primarily driven by high unmet clinical needs in refractory cancers, neurodegenerative disorders, heart failure, diabetes, and inherited retinal diseases. iPSCs provide a continuously expandable cell source, enabling a shift from donor-dependent therapies or patient-specific autologous manufacturing toward standardized, scalable, and potentially off-the-shelf cell products. This transition is gradually enabling batch production and inventory-based supply models in cell replacement therapy, immunotherapy, and tissue regeneration.

Product development is concentrated on allogeneic universal donor approaches, HLA-matched cell banks, low-immunogenicity gene-edited cell lines, CAR-iNK/CAR-iT

platforms, iPSC-derived islet cells, neural progenitor cells, and cardiomyocyte-based therapies. Competitive differentiation is no longer limited to cell type selection, but increasingly depends on stable differentiation protocols, master cell bank quality, detection of residual undifferentiated cells, potency assays, post-thaw functional recovery, and closed-system GMP scale-up capabilities.

Regional opportunities are concentrated in the United States, Japan, China, and Europe. Japan maintains a first-mover advantage in regenerative medicine regulation and iPSC clinical translation, U.S. companies lead in immune cell engineering and financing strength, while Chinese companies are advancing rapidly in neurological disease clinical development. Key risks include tumorigenicity, immune rejection, long-term patient follow-up requirements, high manufacturing costs, and inconsistency in release standards. Companies capable of simultaneously addressing safety, scalability, and clinically validated efficacy are more likely to secure strategic partnerships and industry adoption.

Report Scope

This report studies the global iPSC-Derived Cell Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for iPSC-Derived Cell Therapy, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of iPSC-Derived Cell Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global iPSC-Derived Cell Therapy total market, 2021-2032, (USD Million)

Global iPSC-Derived Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: iPSC-Derived Cell Therapy total market, key domestic companies, and share, (USD Million)

Global iPSC-Derived Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)

Global iPSC-Derived Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)

Global iPSC-Derived Cell Therapy total market by Application, CAGR, 2021-2032, (USD

Million)

This report profiles major players in the global iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fate Therapeutics, Century Therapeutics, Sumitomo Pharma, BlueRock Therapeutics, Heartseed, Sana Biotechnology, Aspen Neuroscience, iRegene Therapeutics, XellSmart, TreeFrog Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world iPSC-Derived Cell Therapy market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global iPSC-Derived Cell Therapy Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global iPSC-Derived Cell Therapy Market, Segmentation by Type:

- iPSC-Derived NK Cell Therapy
- iPSC-Derived T Cell Therapy
- iPSC-Derived Neural Cell Therapy
- iPSC-Derived Cardiomyocyte Therapy
- iPSC-Derived Pancreatic Islet Cell Therapy
- iPSC-Derived Retinal Cell Therapy
- iPSC-Derived Mesenchymal Stromal Cell Therapy
- Other iPSC-Derived Cell Therapy

Global iPSC-Derived Cell Therapy Market, Segmentation by Immune Matching Strategy:

- Standard Allogeneic Therapy
- HLA-Matched Allogeneic Therapy
- Gene-Edited Hypoimmune Therapy
- Autologous Patient-Specific Therapy
- Other Immune Matching Strategy

Global iPSC-Derived Cell Therapy Market, Segmentation by Development Stage:

- Approved or Conditional Approval

Phase III or Pivotal Clinical

Phase II Clinical

Phase I or I/II Clinical

Preclinical or IND-Enabling

Discovery and Research

Global iPSC-Derived Cell Therapy Market, Segmentation by Administration Site:

Intravenous Systemic Delivery

Intracerebral or Putaminal Delivery

Intramyocardial Delivery

Subretinal or Ocular Delivery

Intra-Articular Delivery

Topical or Implantable Dressing

Other Local Delivery

Global iPSC-Derived Cell Therapy Market, Segmentation by Application:

Oncology

Neurological Disorders

Cardiovascular Diseases

Diabetes and Metabolic Diseases

Ophthalmic Diseases

Other Regenerative and Immune Diseases

Companies Profiled:

Fate Therapeutics

Century Therapeutics

Sumitomo Pharma

BlueRock Therapeutics

Heartseed

Sana Biotechnology

Aspen Neuroscience

iRegene Therapeutics

XellSmart

TreeFrog Therapeutics

Cynata Therapeutics

Shoreline Biosciences

Evotec

FUJIFILM Cellular Dynamics

Opsis Therapeutics

Cellistic

Key Questions Answered

1. How big is the global iPSC-Derived Cell Therapy market?
2. What is the demand of the global iPSC-Derived Cell Therapy market?
3. What is the year over year growth of the global iPSC-Derived Cell Therapy market?
4. What is the total value of the global iPSC-Derived Cell Therapy market?
5. Who are the Major Players in the global iPSC-Derived Cell Therapy market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 iPSC-Derived Cell Therapy Introduction

1.2 World iPSC-Derived Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)

1.3 World iPSC-Derived Cell Therapy Total Market by Region (by Headquarter Location)

1.3.1 World iPSC-Derived Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)

1.3.2 United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.3 China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.4 Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.5 Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.6 South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.7 ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.3.8 India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032)

1.4 Market Drivers, Restraints and Trends

1.4.1 iPSC-Derived Cell Therapy Market Drivers

1.4.2 Factors Affecting Demand

1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.2 World iPSC-Derived Cell Therapy Consumption Value by Region

2.2.1 World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026)

2.2.2 World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032)

2.3 United States iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.4 China iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.5 Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.6 Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.7 South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.8 ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032)

2.9 India iPSC-Derived Cell Therapy Consumption Value (2021-2032)

3 WORLD IPSC-DERIVED CELL THERAPY COMPANIES COMPETITIVE ANALYSIS

- 3.1 World iPSC-Derived Cell Therapy Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global iPSC-Derived Cell Therapy Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for iPSC-Derived Cell Therapy in 2025
 - 3.2.3 Global Concentration Ratios (CR8) for iPSC-Derived Cell Therapy in 2025
- 3.3 iPSC-Derived Cell Therapy Company Evaluation Quadrant
- 3.4 iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
 - 3.4.1 iPSC-Derived Cell Therapy Market: Region Footprint
 - 3.4.2 iPSC-Derived Cell Therapy Market: Company Product Type Footprint
 - 3.4.3 iPSC-Derived Cell Therapy Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: iPSC-Derived Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: iPSC-Derived Cell Therapy Consumption Value Comparison
 - 4.2.1 United States VS China: iPSC-Derived Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
 - 4.3.1 United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)
- 4.4 China Based Companies iPSC-Derived Cell Therapy Revenue and Market Share,

2021-2026

4.4.1 China Based iPSC-Derived Cell Therapy Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026)

4.5 Rest of World Based iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026

4.5.1 Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World iPSC-Derived Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 iPSC-Derived NK Cell Therapy

5.2.2 iPSC-Derived T Cell Therapy

5.2.3 iPSC-Derived Neural Cell Therapy

5.2.4 iPSC-Derived Cardiomyocyte Therapy

5.2.5 iPSC-Derived Pancreatic Islet Cell Therapy

5.2.6 iPSC-Derived Retinal Cell Therapy

5.2.7 iPSC-Derived Mesenchymal Stromal Cell Therapy

5.2.8 Other iPSC-Derived Cell Therapy

5.3 Market Segment by Type

5.3.1 World iPSC-Derived Cell Therapy Market Size by Type (2021-2026)

5.3.2 World iPSC-Derived Cell Therapy Market Size by Type (2027-2032)

5.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY IMMUNE MATCHING STRATEGY

6.1 World iPSC-Derived Cell Therapy Market Size Overview by Immune Matching Strategy: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Immune Matching Strategy

6.2.1 Standard Allogeneic Therapy

6.2.2 HLA-Matched Allogeneic Therapy

6.2.3 Gene-Edited Hypoimmune Therapy

6.2.4 Autologous Patient-Specific Therapy

6.2.5 Other Immune Matching Strategy

6.3 Market Segment by Immune Matching Strategy

6.3.1 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2021-2026)

6.3.2 World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032)

6.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2027-2032)

7 MARKET ANALYSIS BY DEVELOPMENT STAGE

7.1 World iPSC-Derived Cell Therapy Market Size Overview by Development Stage: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Development Stage

7.2.1 Approved or Conditional Approval

7.2.2 Phase III or Pivotal Clinical

7.2.3 Phase II Clinical

7.2.4 Phase I or I/II Clinical

7.2.5 Preclinical or IND-Enabling

7.2.6 Discovery and Research

7.3 Market Segment by Development Stage

7.3.1 World iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026)

7.3.2 World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032)

7.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2027-2032)

8 MARKET ANALYSIS BY ADMINISTRATION SITE

8.1 World iPSC-Derived Cell Therapy Market Size Overview by Administration Site: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Administration Site

8.2.1 Intravenous Systemic Delivery

8.2.2 Intracerebral or Putaminal Delivery

8.2.3 Intramyocardial Delivery

8.2.4 Subretinal or Ocular Delivery

8.2.5 Intra-Articular Delivery

8.2.6 Topical or Implantable Dressing

8.2.7 Other Local Delivery

8.3 Market Segment by Administration Site

8.3.1 World iPSC-Derived Cell Therapy Market Size by Administration Site (2021-2026)

8.3.2 World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032)

8.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2027-2032)

9 MARKET ANALYSIS BY APPLICATION

9.1 World iPSC-Derived Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032

9.2 Segment Introduction by Application

9.2.1 Oncology

9.2.2 Neurological Disorders

9.2.3 Cardiovascular Diseases

9.2.4 Diabetes and Metabolic Diseases

9.2.5 Ophthalmic Diseases

9.2.6 Other Regenerative and Immune Diseases

9.3 Market Segment by Application

9.3.1 World iPSC-Derived Cell Therapy Market Size by Application (2021-2026)

9.3.2 World iPSC-Derived Cell Therapy Market Size by Application (2027-2032)

9.3.3 World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)

10 COMPANY PROFILES

10.1 Fate Therapeutics

10.1.1 Fate Therapeutics Details

10.1.2 Fate Therapeutics Major Business

10.1.3 Fate Therapeutics iPSC-Derived Cell Therapy Product and Services

10.1.4 Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

10.1.5 Fate Therapeutics Recent Developments/Updates

10.1.6 Fate Therapeutics Competitive Strengths & Weaknesses

10.2 Century Therapeutics

10.2.1 Century Therapeutics Details

10.2.2 Century Therapeutics Major Business

- 10.2.3 Century Therapeutics iPSC-Derived Cell Therapy Product and Services
- 10.2.4 Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 10.2.5 Century Therapeutics Recent Developments/Updates
- 10.2.6 Century Therapeutics Competitive Strengths & Weaknesses
- 10.3 Sumitomo Pharma
 - 10.3.1 Sumitomo Pharma Details
 - 10.3.2 Sumitomo Pharma Major Business
 - 10.3.3 Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services
 - 10.3.4 Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.3.5 Sumitomo Pharma Recent Developments/Updates
 - 10.3.6 Sumitomo Pharma Competitive Strengths & Weaknesses
- 10.4 BlueRock Therapeutics
 - 10.4.1 BlueRock Therapeutics Details
 - 10.4.2 BlueRock Therapeutics Major Business
 - 10.4.3 BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services
 - 10.4.4 BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.4.5 BlueRock Therapeutics Recent Developments/Updates
 - 10.4.6 BlueRock Therapeutics Competitive Strengths & Weaknesses
- 10.5 Heartseed
 - 10.5.1 Heartseed Details
 - 10.5.2 Heartseed Major Business
 - 10.5.3 Heartseed iPSC-Derived Cell Therapy Product and Services
 - 10.5.4 Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.5.5 Heartseed Recent Developments/Updates
 - 10.5.6 Heartseed Competitive Strengths & Weaknesses
- 10.6 Sana Biotechnology
 - 10.6.1 Sana Biotechnology Details
 - 10.6.2 Sana Biotechnology Major Business
 - 10.6.3 Sana Biotechnology iPSC-Derived Cell Therapy Product and Services
 - 10.6.4 Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.6.5 Sana Biotechnology Recent Developments/Updates
 - 10.6.6 Sana Biotechnology Competitive Strengths & Weaknesses
- 10.7 Aspen Neuroscience
 - 10.7.1 Aspen Neuroscience Details

- 10.7.2 Aspen Neuroscience Major Business
- 10.7.3 Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services
- 10.7.4 Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 10.7.5 Aspen Neuroscience Recent Developments/Updates
- 10.7.6 Aspen Neuroscience Competitive Strengths & Weaknesses
- 10.8 iRegene Therapeutics
 - 10.8.1 iRegene Therapeutics Details
 - 10.8.2 iRegene Therapeutics Major Business
 - 10.8.3 iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services
 - 10.8.4 iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.8.5 iRegene Therapeutics Recent Developments/Updates
 - 10.8.6 iRegene Therapeutics Competitive Strengths & Weaknesses
- 10.9 XellSmart
 - 10.9.1 XellSmart Details
 - 10.9.2 XellSmart Major Business
 - 10.9.3 XellSmart iPSC-Derived Cell Therapy Product and Services
 - 10.9.4 XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.9.5 XellSmart Recent Developments/Updates
 - 10.9.6 XellSmart Competitive Strengths & Weaknesses
- 10.10 TreeFrog Therapeutics
 - 10.10.1 TreeFrog Therapeutics Details
 - 10.10.2 TreeFrog Therapeutics Major Business
 - 10.10.3 TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services
 - 10.10.4 TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.10.5 TreeFrog Therapeutics Recent Developments/Updates
 - 10.10.6 TreeFrog Therapeutics Competitive Strengths & Weaknesses
- 10.11 Cynata Therapeutics
 - 10.11.1 Cynata Therapeutics Details
 - 10.11.2 Cynata Therapeutics Major Business
 - 10.11.3 Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
 - 10.11.4 Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.11.5 Cynata Therapeutics Recent Developments/Updates
 - 10.11.6 Cynata Therapeutics Competitive Strengths & Weaknesses
- 10.12 Shoreline Biosciences

- 10.12.1 Shoreline Biosciences Details
- 10.12.2 Shoreline Biosciences Major Business
- 10.12.3 Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
- 10.12.4 Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 10.12.5 Shoreline Biosciences Recent Developments/Updates
- 10.12.6 Shoreline Biosciences Competitive Strengths & Weaknesses
- 10.13 Evotec
 - 10.13.1 Evotec Details
 - 10.13.2 Evotec Major Business
 - 10.13.3 Evotec iPSC-Derived Cell Therapy Product and Services
 - 10.13.4 Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.13.5 Evotec Recent Developments/Updates
 - 10.13.6 Evotec Competitive Strengths & Weaknesses
- 10.14 FUJIFILM Cellular Dynamics
 - 10.14.1 FUJIFILM Cellular Dynamics Details
 - 10.14.2 FUJIFILM Cellular Dynamics Major Business
 - 10.14.3 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
 - 10.14.4 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.14.5 FUJIFILM Cellular Dynamics Recent Developments/Updates
 - 10.14.6 FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
- 10.15 Opsi Therapeutics
 - 10.15.1 Opsi Therapeutics Details
 - 10.15.2 Opsi Therapeutics Major Business
 - 10.15.3 Opsi Therapeutics iPSC-Derived Cell Therapy Product and Services
 - 10.15.4 Opsi Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.15.5 Opsi Therapeutics Recent Developments/Updates
 - 10.15.6 Opsi Therapeutics Competitive Strengths & Weaknesses
- 10.16 Cellistic
 - 10.16.1 Cellistic Details
 - 10.16.2 Cellistic Major Business
 - 10.16.3 Cellistic iPSC-Derived Cell Therapy Product and Services
 - 10.16.4 Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 10.16.5 Cellistic Recent Developments/Updates
 - 10.16.6 Cellistic Competitive Strengths & Weaknesses

11 INDUSTRY CHAIN ANALYSIS

- 11.1 iPSC-Derived Cell Therapy Industry Chain
- 11.2 iPSC-Derived Cell Therapy Upstream Analysis
- 11.3 iPSC-Derived Cell Therapy Midstream Analysis
- 11.4 iPSC-Derived Cell Therapy Downstream Analysis

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

- 13.1 Methodology
- 13.2 Research Process and Data Source
- 13.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World iPSC-Derived Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World iPSC-Derived Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World iPSC-Derived Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key iPSC-Derived Cell Therapy Players in 2025

Table 12. World iPSC-Derived Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global iPSC-Derived Cell Therapy Company Evaluation Quadrant

Table 14. Head Office of Key iPSC-Derived Cell Therapy Players

Table 15. iPSC-Derived Cell Therapy Market: Company Product Type Footprint

Table 16. iPSC-Derived Cell Therapy Market: Company Product Application Footprint

Table 17. iPSC-Derived Cell Therapy Mergers & Acquisitions Activity

Table 18. United States VS China iPSC-Derived Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China iPSC-Derived Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)

Table 21. United States Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)

Table 23. China Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)

Table 24. China Based Companies iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)

Table 26. Rest of World Based iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)

Table 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World iPSC-Derived Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World iPSC-Derived Cell Therapy Market Size by Type (2027-2032) & (USD Million)

Table 32. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032

Table 33. World iPSC-Derived Cell Therapy Market Size Value by Immune Matching Strategy (2021-2026) & (USD Million)

Table 34. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy (2027-2032) & (USD Million)

Table 35. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032

Table 36. World iPSC-Derived Cell Therapy Market Size Value by Development Stage (2021-2026) & (USD Million)

Table 37. World iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032) & (USD Million)

Table 38. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032

Table 39. World iPSC-Derived Cell Therapy Market Size Value by Administration Site (2021-2026) & (USD Million)

Table 40. World iPSC-Derived Cell Therapy Market Size by Administration Site (2027-2032) & (USD Million)

Table 41. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million),

2021 & 2025 & 2032

Table 42. World iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (USD Million)

Table 43. World iPSC-Derived Cell Therapy Market Size by Application (2027-2032) & (USD Million)

Table 44. Fate Therapeutics Basic Information, Manufacturing Base and Competitors

Table 45. Fate Therapeutics Major Business

Table 46. Fate Therapeutics iPSC-Derived Cell Therapy Product and Services

Table 47. Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 48. Fate Therapeutics Recent Developments/Updates

Table 49. Fate Therapeutics Competitive Strengths & Weaknesses

Table 50. Century Therapeutics Basic Information, Manufacturing Base and Competitors

Table 51. Century Therapeutics Major Business

Table 52. Century Therapeutics iPSC-Derived Cell Therapy Product and Services

Table 53. Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 54. Century Therapeutics Recent Developments/Updates

Table 55. Century Therapeutics Competitive Strengths & Weaknesses

Table 56. Sumitomo Pharma Basic Information, Manufacturing Base and Competitors

Table 57. Sumitomo Pharma Major Business

Table 58. Sumitomo Pharma iPSC-Derived Cell Therapy Product and Services

Table 59. Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 60. Sumitomo Pharma Recent Developments/Updates

Table 61. Sumitomo Pharma Competitive Strengths & Weaknesses

Table 62. BlueRock Therapeutics Basic Information, Manufacturing Base and Competitors

Table 63. BlueRock Therapeutics Major Business

Table 64. BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Services

Table 65. BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 66. BlueRock Therapeutics Recent Developments/Updates

Table 67. BlueRock Therapeutics Competitive Strengths & Weaknesses

Table 68. Heartseed Basic Information, Manufacturing Base and Competitors

Table 69. Heartseed Major Business

Table 70. Heartseed iPSC-Derived Cell Therapy Product and Services

Table 71. Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market

Share (2021-2026) & (USD Million)

Table 72. Heartseed Recent Developments/Updates

Table 73. Heartseed Competitive Strengths & Weaknesses

Table 74. Sana Biotechnology Basic Information, Manufacturing Base and Competitors

Table 75. Sana Biotechnology Major Business

Table 76. Sana Biotechnology iPSC-Derived Cell Therapy Product and Services

Table 77. Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 78. Sana Biotechnology Recent Developments/Updates

Table 79. Sana Biotechnology Competitive Strengths & Weaknesses

Table 80. Aspen Neuroscience Basic Information, Manufacturing Base and Competitors

Table 81. Aspen Neuroscience Major Business

Table 82. Aspen Neuroscience iPSC-Derived Cell Therapy Product and Services

Table 83. Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 84. Aspen Neuroscience Recent Developments/Updates

Table 85. Aspen Neuroscience Competitive Strengths & Weaknesses

Table 86. iRegene Therapeutics Basic Information, Manufacturing Base and Competitors

Table 87. iRegene Therapeutics Major Business

Table 88. iRegene Therapeutics iPSC-Derived Cell Therapy Product and Services

Table 89. iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 90. iRegene Therapeutics Recent Developments/Updates

Table 91. iRegene Therapeutics Competitive Strengths & Weaknesses

Table 92. XellSmart Basic Information, Manufacturing Base and Competitors

Table 93. XellSmart Major Business

Table 94. XellSmart iPSC-Derived Cell Therapy Product and Services

Table 95. XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 96. XellSmart Recent Developments/Updates

Table 97. XellSmart Competitive Strengths & Weaknesses

Table 98. TreeFrog Therapeutics Basic Information, Manufacturing Base and Competitors

Table 99. TreeFrog Therapeutics Major Business

Table 100. TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Services

Table 101. TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 102. TreeFrog Therapeutics Recent Developments/Updates

Table 103. TreeFrog Therapeutics Competitive Strengths & Weaknesses
Table 104. Cynata Therapeutics Basic Information, Manufacturing Base and Competitors
Table 105. Cynata Therapeutics Major Business
Table 106. Cynata Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 107. Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Cynata Therapeutics Recent Developments/Updates
Table 109. Cynata Therapeutics Competitive Strengths & Weaknesses
Table 110. Shoreline Biosciences Basic Information, Manufacturing Base and Competitors
Table 111. Shoreline Biosciences Major Business
Table 112. Shoreline Biosciences iPSC-Derived Cell Therapy Product and Services
Table 113. Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. Shoreline Biosciences Recent Developments/Updates
Table 115. Shoreline Biosciences Competitive Strengths & Weaknesses
Table 116. Evotec Basic Information, Manufacturing Base and Competitors
Table 117. Evotec Major Business
Table 118. Evotec iPSC-Derived Cell Therapy Product and Services
Table 119. Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Evotec Recent Developments/Updates
Table 121. Evotec Competitive Strengths & Weaknesses
Table 122. FUJIFILM Cellular Dynamics Basic Information, Manufacturing Base and Competitors
Table 123. FUJIFILM Cellular Dynamics Major Business
Table 124. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Services
Table 125. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. FUJIFILM Cellular Dynamics Recent Developments/Updates
Table 127. FUJIFILM Cellular Dynamics Competitive Strengths & Weaknesses
Table 128. Opsi Therapeutics Basic Information, Manufacturing Base and Competitors
Table 129. Opsi Therapeutics Major Business
Table 130. Opsi Therapeutics iPSC-Derived Cell Therapy Product and Services
Table 131. Opsi Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Opsi Therapeutics Recent Developments/Updates

Table 133. Opsi Therapeutics Competitive Strengths & Weaknesses

Table 134. Cellistic Basic Information, Manufacturing Base and Competitors

Table 135. Cellistic Major Business

Table 136. Cellistic iPSC-Derived Cell Therapy Product and Services

Table 137. Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 138. Cellistic Recent Developments/Updates

Table 139. Cellistic Competitive Strengths & Weaknesses

Table 140. Global Key Players of iPSC-Derived Cell Therapy Upstream (Raw Materials)

Table 141. Global iPSC-Derived Cell Therapy Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. iPSC-Derived Cell Therapy Picture

Figure 2. World iPSC-Derived Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World iPSC-Derived Cell Therapy Total Revenue (2021-2032) & (USD Million)

Figure 4. World iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)

Figure 13. iPSC-Derived Cell Therapy Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 16. World iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 17. United States iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 18. China iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Million)

Figure 21. South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 23. India iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of iPSC-Derived Cell Therapy by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for iPSC-Derived Cell Therapy Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for iPSC-Derived Cell Therapy Markets in 2025

Figure 27. United States VS China: iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025

Figure 31. iPSC-Derived NK Cell Therapy

Figure 32. iPSC-Derived T Cell Therapy

Figure 33. iPSC-Derived Neural Cell Therapy

Figure 34. iPSC-Derived Cardiomyocyte Therapy

Figure 35. iPSC-Derived Pancreatic Islet Cell Therapy

Figure 36. iPSC-Derived Retinal Cell Therapy

Figure 37. iPSC-Derived Mesenchymal Stromal Cell Therapy

Figure 38. Other iPSC-Derived Cell Therapy

Figure 39. iPSC-Derived Mesenchymal Stromal Cell Therapy

Figure 40. World iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2032)

Figure 41. World iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032

Figure 42. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy in 2025

Figure 43. Standard Allogeneic Therapy

Figure 44. HLA-Matched Allogeneic Therapy

Figure 45. Gene-Edited Hypoimmune Therapy

Figure 46. Autologous Patient-Specific Therapy

Figure 47. Other Immune Matching Strategy

Figure 48. World iPSC-Derived Cell Therapy Market Size Market Share by Immune Matching Strategy (2021-2032)

Figure 49. World iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032

Figure 50. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025

Figure 51. Approved or Conditional Approval

Figure 52. Phase III or Pivotal Clinical

Figure 53. Phase II Clinical

Figure 54. Phase I or I/II Clinical

Figure 55. Preclinical or IND-Enabling

Figure 56. Discovery and Research

Figure 57. World iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2032)

Figure 58. World iPSC-Derived Cell Therapy Market Size by Administration Site, (USD Million), 2021 & 2025 & 2032

Figure 59. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site in 2025

Figure 60. Intravenous Systemic Delivery

Figure 61. Intracerebral or Putaminal Delivery

Figure 62. Intramyocardial Delivery

Figure 63. Subretinal or Ocular Delivery

Figure 64. Intra-Articular Delivery

Figure 65. Topical or Implantable Dressing

Figure 66. Other Local Delivery

Figure 67. Other Local Delivery

Figure 68. World iPSC-Derived Cell Therapy Market Size Market Share by Administration Site (2021-2032)

Figure 69. World iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 70. World iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025

Figure 71. Oncology

Figure 72. Neurological Disorders

Figure 73. Cardiovascular Diseases

Figure 74. Diabetes and Metabolic Diseases

Figure 75. Ophthalmic Diseases

Figure 76. Other Regenerative and Immune Diseases

Figure 77. World iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)

Figure 78. iPSC-Derived Cell Therapy Industrial Chain

Figure 79. Methodology

Figure 80. Research Process and Data Source

I would like to order

Product name: Global iPSC-Derived Cell Therapy Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G5D9D4DC4ABEEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5D9D4DC4ABEEN.html>